
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.
This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
Do you wish to leave this site?
Yes NoBelow is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
Condition :
Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
To give you the best possible user experience, this site uses cookies and by continuing to use this site, you agree that this site saves them on your devices for analytics purposes and to remember your preferences. For more information, please read our terms of use and our Privacy policy.